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Leishmaniasis represents a severe, increasing, public health problem. The perspective of its control 
is highly dependent on research progress, on therapeutic manipulations of the immune system, and on 
vaccine development. There is a correlation between the clinical outcome of Leishmania infection and 
the cytokine response profile. While a protective immune response against Leishmania has been clearly 
identified to be related to the influence of a type-1 response and IFN-γ production, the precise role of 
T helper (T
H
) 2 cytokines in non-healing infections requires further exploration. IL-4 and IL-13 (T
H
2 
cytokines) can promote disease progression in cutaneous leishmaniasis, whereas IL-4 would appear to 
enhance protective type-1 responses in visceral leishmaniasis. Thus, the T
H
1/T
H
2 paradigm of resistance/
susceptibility to intracellular parasites is probably an oversimplification of a more complicated network 
of regulatory/counter regulatory interactions. Moreover, the presence of antigen specific regulatory T 
cell subsets may provide an environment that contributes to the balance between T
H
1 and T
H
2 cells. 
Finally, the involvement of CD8+ T cells has been described, but the modality of their function in this 
kind of infection has not been so far elucidated.
Leishmaniasis represents a severe, increasing 
public health problem (1-2). Moreover, many of the 
50 million people who travel from industrialized 
to developing countries each year report some 
infective illness associated with their travel, included 
leishmaniasis, which is endemic in the areas of 
tropics, subtropics, and southern Europe (3). The 
perspective of control is still highly dependent on 
research progresses, to obtain better tools and more 
cost-effective strategy for vector control and case 
management, through therapeutic manipulations of 
the immune system, and  vaccine development (4).
Leishmaniasis comprises a group of diseases 
caused by protozoan parasites of the Leishmania 
genus. Leishmaniasis is characterized by different 
clinical manifestations, which are dependent not 
only on host genetic control, but also on the infecting 
species, which to date are more than 20 (5). 
The parasites which  cause the various forms 
of leishmaniasis in humans are classified in 
the subgenus Leishmania (L.) or Viannia (V.). 
Cutaneous leishmaniasis (CL) is caused, in the 
Old World, by Leishmania (L.) major, Leishmania 
(L.) aethiopica, and dermotropic Leishmania (L.) 
infantum, of the Leishmania subgenus; in the New 
World, by Leishmania (L.) mexicana, Leishmania 
(L.) amazonensis, Leishmania (L.) venezuelensis, 
and dermotropic Leishmania (L.) infantum, 
of the Leishmania subgenus, and Leishmania 
(V.) braziliensis, Leishmania (V.) guyanensis, 
Leishmania (V.) lainsoni, Leishmania (V.) naiffi, 
Leishmania (V.) panamensis, Leishmania (V.) 
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promastigotes, inoculated with the sandfly saliva, 
enter macrophages to evade host responses. 
Progressive intracellular infection by amastigotes 
depends on the maintenance of macrophages in an 
inert, deactivated state. At the same time, however, 
the immunocompetent host is equipped to respond 
both with non-specific (innate) and antigen-specific 
(adaptive) cell-mediated mechanisms. These 
inflammatory responses mediate disease evolution 
and may (self-healing disease or asymptomatic 
infection) or may not (non-healing disease) 
produce the desired clinical end-result (8, 12). At 
the site of infection, innate responses include cells 
(neutrophils, monocytes, macrophages, natural killer 
[NK] cells, and dendritic cells), Pattern Recognition 
Receptors (PPRs, i.e. toll-like receptors), and 
soluble products (complement, and released 
cytokines, including interleukin [IL]-1α, IL-12, 
Tumor Necrosis Factor [TNF]). Innate mechanisms, 
especially IL-12 secretion, drive the parallel 
induction of cell-mediated immunity. This complex 
set of mechanisms leads to the activation of specific 
CD4+ and CD8+ T cells. These effector T cells 
circulate, are recruited to cutaneous or visceral sites 
via adhesion molecules and chemokine mechanisms, 
and, along with influxing blood monocytes, direct 
local inflammatory responses, including granuloma 
assembly and lesion development (13-15). 
The site of Leishmania infection in the dermis of 
patients affected by CL is characterized by a massive 
infiltration of macrophages and chemokines, such 
as Monocyte Chemoattractant Protein-1 (MCP-1), 
monokine induced by interferon (IFN)-γ (MIG), 
IFN-γ-inducible protein 10 (IP-10), and only a low 
amount of macrophage inflammatory protein 1α 
(MIP-1α) (16-17). In skin lesions of patients with 
self-healing CL, the healing process is facilitated 
by high levels of MCP-1 expression, whereas 
high local levels of MIP-1α are associated with 
the non-healing form of CL. MCP-1 and IFN-
γ synergistically activate monocytes to clear 
intracellular parasites, whereas IL-4 abrogates the 
effect of MCP-1 (16-17). Predominant T helper 
(T
H
)1-type cell responses are associated with IFN-
γ-induced macrophage activation, indicating a 
network of pleiotropic cytokines, in which IL-12, 
produced by activated antigen presenting cells 
(APC), such as macrophages and dendritic cells, 
peruviana, and Leishmania shawi, of the Viannia 
subgenus. Mucocutaneous leishmaniasis (MCL), 
or espundia, is caused by Leishmaniasis (V.) 
braziliensis, and Leishmania (V.) panamensis, 
whereas visceral leishmaniasis (VL), also known as 
‘Kala Azar’, is caused by Leishmania (L.) infantum 
in the Mediterranean area, Middle-East and Asian 
countries, and Leishmania (L.) chagasi in Latin 
America. Leishmania (L.) mexicana and Leishmania 
(L.) amazonensis are now regarded as a single specie, 
due to their genotypic relationships, within the 
Leishmania mexicana complex, whereas Leishmania 
(L.) infantum and Leishmania (L.) chagasi, together 
with Leishmania (L.) donovani, are now regarded as 
a single specie, due to their genotypic relationships, 
within the Leishmania donovani complex. After 
recovery, patients may develop a chronic CL form, 
called ‘Post-Kala Azar Dermal Leishmaniasis’ 
(PKDL), which usually requires  long and expensive 
treatment (6-7).
Leishmania spp. are digenetic parasites, that 
develop as flagellated motile promastigotes in the 
gut of blood-sucking female sand flies (Phlebotomus 
spp. in the Old Word, Lutzomyia spp. in the New 
World), transmitted into the dermis of the vertebrate 
host during the ingestion of a blood-meal, and as 
obligate intracellular non-motile amastigotes in 
the phagolysosomes of macrophages and dendritic 
cell lineage of the vertebral hosts. Leishmaniasis 
is mainly a zoonotic disease and a wide range of 
mammals act as reservoirs, particularly rodents, 
edentates and marsupials in CL, wild canines and 
domestic dogs in zoonotic VL. In anthroponotic 
VL (widespread in India) man is the sole source of 
infection for the vector (8-9). 
All species of Leishmania infect mice relatively 
easily, producing diseases facilitating their utilisation 
as in vivo models, not only to evaluate the host 
genetic control of infection, but also to determine 
how immune responses develop and are regulated 
(10-11). 
Immune responses in animal and human 
leishmaniasis
General aspects
Parasite factors and host mechanisms are 
inextricably linked with the pathogenesis of 
leishmaniasis. To initially establish the infection, 
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produce, together with  NK cells, IFN-γ, as antigen-
specific acquired cell-mediated response (21-23).
Major Histocompatibility Complex (MCH) 
class II antigen presentation alone is not sufficient 
to activate T
H
1 cell responses and ligation of co-
stimulatory molecules (i.e. B7-1/B7-2 and CD40 
on the APC with CD28 and CD40L on the T
H
1 cell, 
respectively) is also a prerequisite (24-25). IFN-γ 
from T
H
1 cells, and probably to a lesser extent CD8+ 
T cells (as part of the antigen-specific acquired cell-
mediated immune response), but also from IL-12 
activated NK cells, as part of the innate response, 
mediate macrophage activation, superoxide (O
2
-
) and nitric oxide (NO) production, and parasite 
killing. Although the molecular mechanism of the 
action of NO on Leishmania is to date unknown, 
early data suggested that NO is directly cytotoxic to 
the parasites (26-27). The NO-pathway thus appears 
to be a common mechanism of Leishmania killing. 
Moreover, macrophage leishmanicidal activity, 
induced by IFN-γ, has been shown to be enhanced 
by other cytokines, such as TNF-α, Migration 
Inhibitor Factor (MIF) and type-1 interferons 
shapes the basic response, and IFN-γ and other 
cytokines also participate (18). However, in patients 
with clinically apparent infections, especially acute 
VL (see below), T
H
1- and T
H
2-type responses are not 
characteristically polarised, as both activating (i.e. 
IL-12, IFN-γ) and suppressive (i.e. IL-4, IL-10, IL-
13, Transforming Growth Factor [TGF]-β) cytokines 
are detected (19-20). It is possible that in acute 
leishmaniasis counterbalancing mechanisms are 
normally produced to curtail the process (19-20). IL-
4, IL-10, IL-13 and TGF-β are capable of derailing 
T
H
1-type responses and deactivating macrophages, 
thereby moderating tissue injury, but promoting 
intracellular infection (19-20). 
Resolution of infection: the T
H
1 response
It is now well established that a protective 
immune response against CL is dependent on the 
development of a potent type-1 response (15). The 
general consensus is that IL-12, from activated APC, 
possibly augmented by other cytokines (IL-1α, IL-
18, IL-23 and IL-27, as innate mechanism) drives the 
differentiation and proliferation of T
H
1 cells, which 
Table 1. Types of CD4+ T-cells and cytokines involved in different forms of leishmaniasis.
Healing Non healing Disease
CD4+ T-cell Cytokines  CD4+ T-cell Cytokines 
Cutaneous leishmaniasis TH1 Leishmania major, mexicana, amazonensis: 
IL-12, IL-1�, IL-18, 
IL-23, IL-27, IFN-�,
TNF-�, MIF, IFN-�,
IFN-�, GM-CSF, IL-10, TGF-�
Leishmania major: 
excessive TH2 response 
and/or defective APC function 
and/or defective TH1 response 
Leishmania mexicana: 
excessive TH2 response 
and/or defective APC function 
and/or defective TH1 response 
Leishmania amazonensis: 
excessive TH2 response 
and/or defective APC function 
and/or defective TH1 response 
IL-4 (?), IL-13, 
IL-10, TGF-�
IL-4, IL-13 (?),
IL-10 (?) 
IL-4 (?) 
Visceral leishmaniasis TH1
TH2 (?) 
TH1
TH2 (?) 
IL-4 (?), IL-12 
(experimental visceral leishmaniasis) 
IL-2, IFN-�, IL-12, IL-15, IL-4 (?) 
(human visceral leishmaniasis) 
Experimental visceral leishmaniasis:
defective TH1 response (?) 
excessive TH2 response (?) 
Human visceral leishmaniasis: 
defective TH1 response (?)  
excessive TH2 response (?) 
IL-4 (?), IL-10,  
TGF-� (?) 
IL-4 (?), IL-10, 
TGF-� (?) 
CD: cluster of differentiation     TH1: T helper 1              TH2: T helper 2                   APC: antigen presenting cells          IL: interleukin 
IFN-�: interferon-�                    IFN-�: interferon-�        IFN-�: interferon-�             MIF: Migration Inhibitor Factor
TGF-�: Transforming Growth Factor-�           TNF-�: Tumor Necrosis Factor-�      GM-CSF: Granulocyte Macrophage-Colony Stimulating Factor 
Table 1. Types of CD4+ T-cells and cytokines involved in different forms of leishmaniasis.
CD: cluster of differentiation T
H
1: T helper 1 T
H
2: T helper 2 APC: antigen presenting cells IL: interleukin
IFN-α: interferon-α IFN-β: interferon-β IFN-γ: interferon-γ MIF: Migration Inhibitor Factor   
TGF-β: Transforming Growth Factor-β TNF-α: Tumor Necrosis Factor-α GM-CSF: Granulocyte Macrophage-Colony 
Stimulating Factor
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(IFN-α subtypes and IFN-β subtype), Granulocyte 
Macrophage-Colony Stimulating Factor (GM-CSF), 
as well as by CD40/CD40L interactions (28-29). 
For the development of an adequate T
H
1-
mediated resistance to Leishmania infection, another 
important pathway is the Fas/FasL interaction. 
Activated T
H
1 cells induce apoptotic death in target 
cells expressing the Fas protein (30). Macrophages, 
infected with Leishmania, upregulates Fas, in 
response to IFN-γ, and become susceptible to CD4+ 
T cell-induced apoptotic death (30-31). Thus, Fas-
induced apoptotic death of infected macrophages 
might limit the number of host cells at the site 
of infection which are required for amastigote 
replication (30-31). 
Following resolution of infection, concomitant 
immunity is dependent upon antigen-specific CD4+/
CD25+ T-regulatory cells, producing IL-10 and TGF-
β, that moderate the activity of T effectors (32-33). 
In the absence of persistent infection, protective 
immunity is significantly reduced (32-33).
Non-healing cutaneous Leishmania major 
infection: T
H
2-dependent or defective T
H
1 response
The T
H
1-T
H
2 paradigm of resistance/
susceptibility to intracellular infection is largely 
based on investigations using Leishmania major. 
Initial studies have suggested that the resolution or 
progression of disease is dependent on distinct CD4+ 
T cell subsets, T
H
1 and T
H
2, producing the counter 
regulatory cytokines IFN-γ and IL-4, respectively 
(34-35). However, contradictory reports have been 
published indicating a disease progression role 
for IL-4 (36). These studies posed two significant 
questions: firstly, could other regulatory cytokines 
be responsible for the immunosuppressive activity 
previously attributed to IL-4, and/or secondly, could 
the well documented defective T
H
1 response play a 
major role in progressive disease? 
Recent studies, using gene-deficient and 
transgenic mice, have clearly identified other 
cytokines in addition to IL-4 having major roles 
in the non-healing response to Leishmania major 
(36-37). Particularly, IL-13 has been found to act 
independently of IL-4, and the effects of IL-13 and 
IL-4 might be additive (37). Other studies suggest 
that IL-10 is at least as influential as IL-13 and IL-4 
in promoting Leishmania major disease progression. 
IL-10 might play a key role in the pathogenesis of 
leishmaniasis, especially in the down-regulation of 
T
H
1 responses, as supported by the observations 
of suppression of IL-12 production by APC, and 
of IFN-γ production by CD4+ T and NK cells, and 
of macrophage deactivation and inhibition of their 
leishmanicidal functions. T regulatory cells are also 
significant producers of TGF-β, which is also partly 
responsible for suppressing protective responses 
(36-38).
The inability to mount a T
H
1 response, 
irrespective of a T
H
2 response, has been attributed 
to an inability to produce or respond to IL-12, and, 
therefore, to intrinsic defects in APC function or 
in T
H
1 cell development. Defective APC function, 
attributable to a failure to produce IL-12, may also 
underlie in a deficient APC IL-1 production (39). As 
a matter of fact, IL-1 upregulates IL-12 production, 
as well as MHC class II co-stimulatory molecule 
expression, and mediates the ability of IFN-γ to 
inhibit T
H
2 response (39). 
On the contrary, intrinsic defective T
H
1 cell 
development, originally identified as an inability 
to respond to IL-12, has been associated with a 
downregulation of T
H
1 cell IL-12Rβ2 expression 
(40). It is well established that IL-12Rβ2 expression 
can be downregulated by IL-4 produced by T
H
2, 
even though IL-4-indipendent mechanisms have also 
been described (40). A recently described defective 
co-polarization of the T cell receptor (TCR) and 
the IFN-γ receptor complex in naive CD4+ T cells 
during the APC/T precursor interaction, would 
also significantly favour a commitment to T
H
2 
development (39-40).
Non-healing cutaneous Leishmania mexicana/
Leishmania amazonensis infection: IL-4-dependent
In non-healing cutaneous Leishmania mexicana 
infection IL-4 appears to exert the major contribution, 
whereas IL-13 and IL-10 are only partially involved 
(41). The Cathepsin L-like cysteine peptidase 
(CPB) has been identified as the likely Leishmania 
mexicana/Leishmania amazonensis virulence factor 
inducing IL-4 production (42).
While studies on Leishmania mexicana have 
clearly shown a major disease exacerbating role 
for IL-4, that might subvert the development of a 
T
H
1-response, similar studies, on the closely related 
P. MANSUETO ET AL.
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IL-12 shifts the responses toward a T
H
1-type and 
enhances IFN-γ production (54). These findings 
therefore suggest that, in patients with active VL, 
the cytokine profile is not clearly polarized, and both 
T
H
1-like and T
H
2-like cells appear to proliferate and 
to be activated (46, 50, 55). The balance of cytokines 
at the site of primary activation of the Leishmania-
specific cells appears to be of major importance 
for the development of T
H
1 and T
H
2 responses 
(56-57), even though other unknown factors might 
influence the cellular immune response. Altogether, 
data indicate that in symptomatic patients T
H
1 
cytokine production is not depressed, but there is an 
unresponsiveness to the stimuli of these cytokines, 
also caused by the high production of IL-10. 
Recently, another lymphokine, IL-15, was studied 
for its role against infectious diseases (58) and for its 
ability to enhance both T
H
1 responses, by increasing 
IFN-γ production from NK and T cells (59), and T
H
2 
responses, by augmenting IL-5 and IL-13 production 
(60). In particular, it has been demonstrated that 
endogenous IL-15 plays a role in the suppression 
of T
H
2 cytokines in acute VL patients, even though 
it does not enhance the production of T
H
1 cytokines 
(61), indicating a potential protective role of IL-15 
against leishmaniasis caused by the indirect effect 
on T
H
1, due to the restriction of T
H
2 proliferation 
(61). Furthermore, it has been demonstrated that 
the activation of macrophage cultures with IL-15 
determines a significant anti-Leishmania activity 
(62). The killing of Leishmania in macrophages, 
primed with IL-15, is followed by an increase in 
the IL-12 synthesis (62). Altogether, these data 
indicate that IL-15 could have a role as an activator 
of leishmanicidal activity, directly or indirectly, by 
inducing IL-12 production. 
Non-healing visceral leishmaniasis: T
H
2-
independent?
As already mentioned, the disease progression 
and the exacerbating role for T
H
2 response and IL-
4 production during Leishmania donovani infection 
has yet to be demonstrated. Early studies suggest that 
the differential production of T
H
1 and T
H
2 cytokines 
does not control the rate of cure (45), although the 
production of IFN-γ correlates with resistance, 
T
H
2 cytokines are not so clearly responsible for 
susceptibility (63). 
parasite Leishmania amazonensis, have suggested an 
insignificant role for IL-4 in non-healing infection (43-
44). In this setting, CPB might be directly responsible 
for the inhibition of T
H
1 responses, due to the ability 
of CPB to proteolytically degrade the NF-κB family 
of signalling proteins (43-44). Thus, IL-4 independent 
mechanisms might prevail (43-44). 
Paradox of T
H
1 and T
H
2 in visceral 
leishmaniasis 
The dichotomy of T
H
1 and T
H
2 cell responses 
induced by Leishmania parasites is even less clear 
in VL. In experimental VL by Leishmania donovani, 
the disease progression is due to the failure of an 
appropriate T
H
1 response, rather than to the T
H
2 
cell proliferation (45). In fact, IL-4 has been shown 
to have no exacerbating role in murine VL, and, 
under certain circumstances, it can prime for IL-12 
production and a type-1 response (41). 
In humans infected with Leishmania 
donovani,high concentrations of IL-10 and IFN-γ 
are detected in the sera at the beginning of infection, 
which return to the normal range following 
successful chemotherapy (46-47). By contrast, 
peripheral blood mononuclear cells (PBMC), 
stimulated in vitro with Leishmania antigen, produce 
low levels of IL-10 and IFN-γ when collected at 
the time of the diagnosis, and normal levels when 
assayed after recovery (46-47). IL-4 and IL-2 are 
undetectable in the sera, whereas IL-4 is in high 
concentrations in the supernatants in all the phases 
of the disease (46). IL-2 is significantly reduced 
in the supernatants of actively infected patients, 
returning to the normal level after recovery (46-47). 
Low sera levels of IL-4 might be related to the high 
production of IFN-γ, whereas reduction in IL-2 sera 
levels might be due to the high sera concentration 
of soluble IL-2 receptor (sIL-2R) that binds IL-2 
with a high affinity mechanism (48). In spite of 
the similar secretion pattern of IL-10 and IFN-γ, 
above reported, the control of infection or complete 
recovery seems to be associated with an increased 
production of IL-2 and IFN-γ (49-51). Furthermore, 
IL-10 production correlates with the progression of 
VL (52), and neutralisation of IL-10 with a specific 
monoclonal antibody restores T cell proliferation and 
IFN-γ production in PBMC from acute VL patients 
(53). In vitro studies have also demonstrated that 
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According to this point of view, studies in mice 
have shown that animals deficient in IL-4 and IL-4Rα 
are more susceptible to disease than their wild-type 
counterparts, suggesting that IL-4 may be protective 
in some circumstances, and can promote resistance, 
rather than susceptibility, to intracellular pathogens 
(64). In addition, IL-4 and IL-4Rα signalling are not 
only essential for optimal clearance of Leishmania 
donovani from the liver and for limiting infection in 
the spleen  (following primary infection), but also 
are effective for T cell dependent chemotherapy, and 
for vaccine-induced resistance (65). In the absence 
of IL-4, type-1 responses and IFN-γ production fail 
to be maintained following chemotherapy or fail to 
be induced by vaccination (64-65). Other studies 
indicate that IL-10 is the major immunosuppressive 
cytokine in VL, although TGF-β  has also a significant 
disease-promoting activity (66). Experimental IL-10 
inhibition allows activation of T
H
1 cell responses 
and promotes parasite killing (66-67). Furthermore, 
while the healing process in susceptible mice is IL-
12 dependent, IL-10, but not IL-4 or TGF-β, appears 
to blunt T
H
1-type responses and to determine fatal 
outcome of the disease (21). 
T cell subset modifications in visceral 
leishmaniasis
Although data indicate that Leishmania donovani 
parasites cause alterations of the immune system, with 
immune-depression, the exact mechanism by which 
the parasites induce immune-depression is not clear. 
In patients with symptomatic Leishmania infantum 
infection the levels of CD3+, CD4+ and CD8+ T cells 
are within the normal range (46, 50), whereas acute 
VL patients have markedly reduced levels of memory 
T cells (CD3+/CD45RO+) compared with healthy 
controls, and these cells returned to the normal 
levels following successful chemotherapy (46, 50, 
68-69). On the contrary, the number of memory 
CD4+ T cells is markedly increased in persons with 
asymptomatic infection and positive leishmanin (or 
Montenegro) skin test, intradermically performed 
using a culture of promastigotes as antigen (68). The 
significant increase of memory CD4+ T cells  in this 
group of patients, their relationship with the positive 
leishmanin skin test and acquired immunity needs 
further explanations (68-69). However, T cells are 
strongly activated in acute VL patients, as indicated 
by the elevated number of CD3+ HLA-DR+ and by 
the increase in HLA-DR antigen on these cells (46).
The role of apoptosis and CD8+ T cells in 
Leishmania infection
Previously, it has been shown, both in mice and 
in humans, that the induction of T cell apoptosis 
could be involved in the defective host-cellular 
responses to challenge with pathogenic infectious 
agents (70-73). In experimental VL it has been 
demonstrated that the infection of a susceptible host 
results in CD4+ T cell apoptosis and a decrease in 
T
H
1 cytokine production (73). In particular, it has 
been demonstrated that resistance to Leishmania 
major depends on apoptotic mechanisms, mainly 
operating through the Fas (APO-1/CD95) 
pathway, and singeneic gld and lpr mice, lacking 
a functional Fas system, fail to heal their lesions 
(74). Furthermore, in mice infected with Leishmania 
donovani parasites an increased incidence of T cell 
apoptosis in liver and spleen was observed (75). 
Also in VL patients, both in acute and in healed 
phases of disease, leukocyte apoptosis seems to be 
involved. In fact, monocytes and T lymphocytes 
from acute VL patients show a significantly higher 
level of apoptosis compared with that observed in 
healed subjects. The percentage of apoptotic cells 
was higher in monocytes than in T lymphocytes 
(31). T cells involved in programmed cell death were 
mainly of CD4+ phenotype (31, 76). In particular, 
the subset T
H
1, evaluated by chemokine receptor-
5 (CCR5), was involved in this process and used 
CD95-mediated mechanism (31). The significant 
increase in apoptosis of T
H
1-like subset (15-20% 
of CD4+ cells) is in line with the studies carried 
out in susceptible hosts, showing an enhancement 
of CD4+ T cell apoptosis, particularly of T
H
1-like 
cells, associated with a decrease in T
H
1 cytokine 
production (73). Since, T
H
1 cytokines appear to be 
involved in the protection against leishmaniasis, 
both in experimental models (27, 73) and in human 
infections (57-59), this deletion of CD4+ T
H
1-like 
cells could contribute to the depressed cell-mediated 
immunity in acute VL patients.
On the contrary, in active human localised CL a 
higher frequency of cell death in CD8+ T cells than 
in CD4+ T cells was detected, and these apoptotic 
events were very low in patients with self-healing 
P. MANSUETO ET AL.
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lesions (76). Thus, cell death of some T cells could 
be involved in the failure of cell mediated immunity, 
responsible for severe immune-depression in the 
various forms of leishmaniasis.
The amount of data available suggests that CD8+ 
T cells are involved in leishmanicidal activity, and 
that this activity is modulated by IFN-γ and IL-2 
secretion (77). Many reports have highlighted a 
variety of effector mechanisms by these CD8+ T cells, 
which involves the direct cytotoxic activity, through 
the perforin/granzyme pathway, and the induction 
of apoptosis, via Fas/FasL interaction (76-78). They 
also secrete various cytokines (especially IFN-γ) 
and chemokines (especially the ones belonging 
to the C-C group, i.e. Regulated upon Activation, 
Normal T-cell Expressed, and presumably Secreted 
[RANTES]), that might have a key role in acquired 
cell-mediated immunity against the parasite, i.e. by 
promoting CD4+ T
H
1 cell development (78). 
Perforin/granzyme-mediated direct cytotoxicity, 
as well as induction of apoptosis of parasitized 
macrophages, are candidate mechanisms employed 
by CD8+ T cells in their effort to limit parasite 
multiplication (76). 
Post Kala Azar dermal leishmaniasis
In most cases of PKDL, parasites or parasites 
antigens were observed in all the lesions and were 
able to induce the formation of an inflammatory 
infiltrate, consisting of a mixture of macrophages, 
lymphocytes and plasma cells (79). In patients who 
had high IFN-γ responses to Leishmania antigen in 
vitro, compact epithelioid granulomas were formed 
(80). The inflammatory cells were mainly CD3+, 
and IL-10 was the most prominent cytokine found 
in the lesions (80). However, IFN-γ was found in all 
lesions in varying amounts, whereas the presence of 
IL-4 was variable (79-80).
  
CONCLUSIONS
There is a correlation between the clinical outcome 
of Leishmania infection and the cytokine response 
profile. While a protective immune response against 
Leishmania has been clearly identified as being 
under the influence of a type-1 response and IFN-γ 
production, the precise role of T
H
2 cytokines in non-
healing infections requires careful exploration (see 
the summary in Table I). 
IL-4 and IL-13 (T
H
2 cytokines) can promote 
disease progression in appropriate models of CL, 
whereas the role of IL-4 is not well defined in VL, and 
also its ability to enhance protective type-1 response 
has been described. Thus the T
H
1/T
H
2 paradigm of 
resistance/susceptibility to intracellular parasites is 
an oversimplification of a more complicated network 
of regulatory/counter-regulatory interactions. The 
role of IL-4 in influencing Leishmania infection 
awaits a re-evaluation according to the Leishmania 
species involved, to the host organism used and to 
the tissue site examined. Moreover, the presence 
of antigen specific regulatory T cell subsets may 
provide an environment that contributes to the 
balance between T
H
1 and  T
H
2 cells.
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